Golimumab - Next gen biotech blockbusters

Drug: Golimumab
Company: Johnson & Johnson's Centocor, Schering-Plough

Scoop: Golimumab is a human monoclonal antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is being studied as an every four week subcutaneous injection as well as an intravenous infusion therapy. If approved, golimumab would join the ranks of such anti-TNF blockbusters as Enbrel, Humira and J&J's own Remicade. Golimumab's advantage? The drug requires injections only once a month, compared to higher frequencies for other existing drugs. The companies submitted an NDA for the drug in both the U.S. and Europe last month. 

Golimumab - Next gen biotech blockbusters
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.